Brokers Offer Predictions for TENX Q4 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at Leerink Partnrs issued their Q4 2024 earnings estimates for shares of Tenax Therapeutics in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will earn ($1.23) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q1 2025 earnings at ($1.68) EPS, Q2 2025 earnings at ($1.92) EPS, Q3 2025 earnings at ($2.31) EPS, Q4 2025 earnings at ($2.38) EPS, FY2025 earnings at ($8.29) EPS, FY2026 earnings at ($3.91) EPS, FY2027 earnings at ($4.15) EPS and FY2028 earnings at ($2.69) EPS.

A number of other analysts have also commented on TENX. StockNews.com assumed coverage on Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating on the stock. Guggenheim began coverage on Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 price objective for the company. William Blair began coverage on Tenax Therapeutics in a research note on Monday, September 30th. They issued an “outperform” rating on the stock. Finally, Leerink Partners initiated coverage on Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target for the company. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Tenax Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Tenax Therapeutics Trading Down 0.8 %

NASDAQ:TENX opened at $4.83 on Monday. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $33.44. The firm has a 50-day moving average price of $4.02 and a two-hundred day moving average price of $3.70.

Hedge Funds Weigh In On Tenax Therapeutics

Several hedge funds have recently bought and sold shares of the company. Vestal Point Capital LP bought a new stake in Tenax Therapeutics during the third quarter worth about $288,000. Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics in the third quarter worth approximately $173,000. Finally, Sphera Funds Management LTD. bought a new position in Tenax Therapeutics during the third quarter valued at approximately $101,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.